Search Result

Results for "

degradation agent

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Angiotensin-converting Enzyme (ACE) (2) APC (1) Apoptosis (10) Bacterial (4) Bcl-2 Family (2) Bcr-Abl (1) Biochemical Assay Reagents (1) Carbonic Anhydrase (1) Caspase (1) CDK (1) CMV (2) CRM1 (1) Cuproptosis (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (1) Drug Metabolite (1) Drug-Linker Conjugates for ADC (4) E1/E2/E3 Enzyme (1) Ephrin Receptor (1) FLT3 (1) Histone Methyltransferase (1) Isotope-Labeled Compounds (4) JAK (1) Ligands for E3 Ligase (6) MDM-2/p53 (2) Microtubule/Tubulin (1) Molecular Glues (6) PROTACs (9) RET (1) Small Interfering RNA (siRNA) (2) STING (1) Topoisomerase (2) VEGFR (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (33) Cardiovascular Disease (3) Infection (7) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (2)

By Targets:

ADC Cytotoxin (1)

Angiotensin-converting Enzyme (ACE) (2)

APC (1)

Apoptosis (10)

Bacterial (4)

Bcl-2 Family (2)

Bcr-Abl (1)

Biochemical Assay Reagents (1)

Carbonic Anhydrase (1)

Caspase (1)

CDK (1)

CMV (2)

CRM1 (1)

Cuproptosis (1)

Cytochrome P450 (1)

DNA Alkylator/Crosslinker (1)

Drug Metabolite (1)

Drug-Linker Conjugates for ADC (4)

E1/E2/E3 Enzyme (1)

Ephrin Receptor (1)

FLT3 (1)

Histone Methyltransferase (1)

Isotope-Labeled Compounds (4)

JAK (1)

Ligands for E3 Ligase (6)

MDM-2/p53 (2)

Microtubule/Tubulin (1)

Molecular Glues (6)

PROTACs (9)

RET (1)

Small Interfering RNA (siRNA) (2)

STING (1)

Topoisomerase (2)

VEGFR (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (33)

Cardiovascular Disease (3)

Infection (7)

Inflammation/Immunology (3)

Metabolic Disease (3)

Neurological Disease (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-152227

*PROTAC TYK2 degradation* agent1**	PROTACs JAK	Inflammation/Immunology
PROTAC TYK2 degradation agent1 is a potent and subtype-selective TYK2 degrader. PROTAC TYK2 degradation agent1 has TYK2 degradation activity with DC₅₀ value of 14 nM. PROTAC TYK2 degradation agent1 can be used for the research of autoimmune disease .

HY-144841

Cemsidomide CFT7455	Ligands for E3 Ligase	Cancer
Cemsidomide (CFT7455) is an orally active zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3) degrader. Cemsidomide is an anti-cancer agent that binds with high affinity to the cereblon E3 ligase (K_d of 0.9 nM) (WO2022032132A1; Compound 1) .

HY-162281

PROTAC SOS1 degrader-6

Others Cancer

PROTAC SOS1 degrader-6 (compound 23) is a potent SOS1 PROTACs degrader with synergistic efficacy with KRAS ^G12C inhibitors .

PROTAC SOS1 degrader-6	Others	Cancer
PROTAC SOS1 degrader-6 (compound 23) is a potent SOS1 PROTACs degrader with synergistic efficacy with KRAS ^G12C inhibitors .

HY-162450

Antitumor agent-150	PROTACs MDM-2/p53 Apoptosis	Cancer
Antitumor agent-150 (V10), an anti-breast cancer agent, is a PROTAC-based MDM2 protein degrader (Red: Ganoderic acid A; Black: 4O-PEG linker; Blue: VHL ligand) .

HY-146384

CRM1 degrader 1	CRM1	Cancer
CRM1 degrader 1 (1l) is a low toxic chromosome region maintenance 1 (CRM1) degrader. CRM1 is the sole nuclear exporter of several tumor suppressor, a growth regulatory protein as an attractive cancer agent target. CRM1 degrader 1 induces the apoptosis in gastric carcinoma and selectively inhibits proliferation of gastric cancer .

HY-157570

Anti-inflammatory agent 70	STING	Infection
Anti-inflammatory agent 70 (N-Me-SP23) is a STING protein degrader and inhibits the STING signaling pathway. Anti-inflammatory agent 70 has anti-inflammatory activity .

HY-151958

Antitubercular agent-35	Bacterial	Infection
Antitubercular agent-35 (compound 42l) is an antitubercular agent. Antitubercular agent-35 inhibits the growth of Mtb_H37Rv and *M. Marinum* with MIC₉₀ values of 1.25 and 2 μg/mL, respectively. Antitubercular agent-35 shows the ability of escaping metabolic degradation by human liver microsomes. Antitubercular agent-35 can be used for the research of tuberculosis .

HY-151957

Antitubercular agent 34	Bacterial	Infection
Antitubercular agent 34 (compound 42g) is an antitubercular agent. Antitubercular agent 34 inhibits the growth of Mtb_H37Rv with a MIC₉₀ value of 1.25 μg/mL with the ability of escaping metabolic degradation by human liver microsomes. Antitubercular agent 34 can be used for the research of tuberculosis .

HY-P5819

xStAx-VHLL	Wnt APC PROTACs β-catenin	Cancer
xStAx-VHLL is a PROTAC β-catenin degrader that manifests strong inhibition of Wnt signaling and sustains degradation of β-catenin in cancer cells and the intestinal organoids derived from wild-type and APC ^–/– mice. xStAx-VHLL can be used as a promising anticancer agent .

HY-10984

Pomalidomide Maximum Cited Publications 13 Publications Verification CC-4047	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-115718A

PZ703b TFA 1 Publications Verification	PROTACs Bcl-2 Family	Cancer
PZ703b TFA is a Bcl-xl PROTAC degradation agent that induces apoptosis and inhibits cancer cell proliferation for bladder cancer research .

HY-129478

TC11	Caspase Bcl-2 Family CDK	Cancer
TC11 is a MCL1 degrader. TC11 is also a Caspase-9 and CDK1 activator. TC11 structurally relates to immunomodulatory agents as phenylphthalimide derivative. TC11 induces apoptotic death caused by degradation of MCL1 during prolonged mitotic arrest .

HY-146393

PROTAC CYP1B1 degrader-1	PROTACs Cytochrome P450	Cancer
PROTAC CYP1B1 degrader-1 (Compound 6C), a α-naphthoflavone chimera derivative, is able to eliminate cytochrome P450 (CYP)1B1-mediated agent resistance via targeted CYP1B1 degradation, with IC₅₀s of 95.1 and 9838.6 nM for CYP1B1 and CYP1A2, respectively. PROTAC CYP1B1 degrader-1 can be used for the research of CYP1B1-overexpressing prostate cancer .

HY-B0300S

Penicillamine-d3 D-(-)-Penicillamine-d₃	Drug Metabolite Isotope-Labeled Compounds Cuproptosis	Inflammation/Immunology
Penicillamine-d₃ is the deuterium labeled Penicillamine. Penicillamine (D-(-)-Penicillamine) is the most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.

HY-161324

Tubulin degrader 1	Microtubule/Tubulin	Cancer
Tubulin degrader 1 (Compound 5i) is a BML284 (HY-19987) derivative that is an orally active colchicine-site noncovalent tubulin degradation agent with IC₅₀ values ranging from 0.02 to 0.05 μM against the five tumor cell lines (Hela, HCT116, MCF-7, K562 and Molm-13). Tubulin degrader 1 has antiproliferative activity that effectively suppressed tumor growth .

HY-15578

McMMAF 4 Publications Verification Maleimidocaproyl monomethylauristatin F	Drug-Linker Conjugates for ADC	Cancer
McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-N7449

Neamine	Bacterial	Infection Cardiovascular Disease Neurological Disease Cancer
Neamine, a degradation product of Neomycin, is a broad-spectrum aminoglycoside antibiotic. Neamine is an anti-angiogenesis agent targeting angiogenin. Neamine has potent antibacterial, antitumor and neuroprotective activities .

HY-117878

ML345	Others	Metabolic Disease
ML345 is a potent and selective *insulin-degrading* enzyme (IDE) small-molecule inhibitor, with an IC₅₀** value of 188 nM. ML345 can be for use as a pharmacophore for agent development in diabetes research .

HY-108903

Hyaluronidase (human recombinant) Hylenex; Vorhyaluronidase alfa; rHuPH 20	Others	Cancer
Hyaluronidase (human recombinant) (Hylenex; Vorhyaluronidase alfa; rHuPH 20),catalysing the degradation of hyaluronic acid, is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents .

HY-101150A

sulfo-DGN462 sodium	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
sulfo-DGN462 sodium is degraded to DGN462 in culture medium and plasma. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML) .

HY-125834

GMB-475	PROTACs Bcr-Abl Apoptosis	Cancer
GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent agent resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein .

HY-115349

Neamine tetrahydrochloride	Bacterial	Infection Neurological Disease Cancer
Neamine tetrahydrochloride, a degradation product of Neomycin, is a broad-spectrum aminoglycoside antibiotic. Neamine tetrahydrochloride is an anti-angiogenesis agent targeting angiogenin. Neamine tetrahydrochloride has potent antibacterial, antitumor and neuroprotective activities .

HY-10984S

Pomalidomide-d5 CC-4047-d₅	Isotope-Labeled Compounds Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Pomalidomide-d₅ is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-10984S2

Pomalidomide-d4 CC-4047-d₄	Isotope-Labeled Compounds Apoptosis Ligands for E3 Ligase Molecular Glues	Cancer
Pomalidomide-d₄ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<

HY-15578G

McMMAF Maleimidocaproyl monomethylauristatin F	Drug-Linker Conjugates for ADC	Cancer
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent .

HY-146368

PROTAC VEGFR-2 degrader-1	PROTACs VEGFR	Cancer
PROTAC VEGFR-2 degrader-1（PROTAC-1）, a PROTAC VEGFR-2 degrader, exhibits little VEGFR-2 inhibition (IC₅₀> 1 μM) and anti-proliferative activity against EA.hy926 cells (IC₅₀> 100 μM) .

HY-146369

PROTAC VEGFR-2 degrader-2	PROTACs VEGFR	Cancer
PROTAC VEGFR-2 degrader-2（PROTAC-4）, a PROTAC VEGFR-2 degrader, exhibits little VEGFR-2 inhibition (IC₅₀> 1 μM) and anti-proliferative activity against EA.hy926 cells (IC₅₀> 100μM) .

HY-10984S1

Pomalidomide-d3 CC-4047-d₃	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Pomalidomide-d₃ is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors[1][2].

HY-127026A

Quinaprilat hydrate	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Quinaprilat hydrate is a non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat hydrate specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat hydrate acts as anti-hypertensive agent and vasodilator .

HY-148380A

Mal-PEG8-Phe-Lys-PAB-Exatecan TFA	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631) .

HY-127026

Quinaprilat	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Quinaprilat is an orally active non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat acts as anti-hypertensive agent and vasodilator .

HY-W093067

KTX-582 intermediate-4	Others	Cancer
KTX-582 intermediate-4 (intermediate 2-1)is a synthesis IRAK4Degrading agent KTX-582 (HY-148274)of intermediates. KTX-582It is also an effective form of apoptosis (apoptosis)inducer .

HY-148380

Mal-PEG8-Phe-Lys-PAB-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Mal-PEG8-Phe-Lys-PAB-Exatecan (compound 15) is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631) composition .

HY-109528

Fomivirsen sodium ISIS-2922	CMV	Infection
Fomivirsen (ISIS-2922) sodium is an antisense 21 mer phosphorothioate oligonucleotide. Fomivirsen sodium is an antiviral agent that is used cytomegalovirus retinitis (CMV) research, incluiding in AIDs. Fomivirsen sodium binds to and degrades the mRNAs encoding CMV immediate-early 2 protein, thus inhibiting virus proliferation .

HY-112958

Fomivirsen ISIS-2922 free base	CMV	Infection
Fomivirsen (ISIS-2922 free base) is an antisense 21 mer phosphorothioate oligonucleotide. Fomivirsen is an antiviral agent that is used CMV research, incluiding in AIDs. Fomivirsen binds to and degrades the mRNAs encoding CMV immediate-early 2 protein, thus inhibiting virus proliferation .

HY-10984S3

Pomalidomide-15N,13C5 CC-4047-¹⁵N,¹³C₅	Molecular Glues Apoptosis Ligands for E3 Ligase Isotope-Labeled Compounds	Cancer
Pomalidomide- ¹⁵N, ¹³C₅ is ¹⁵N and ¹³C labeled Pomalidomide (HY-10984). Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

HY-P3717

Targefrin	Ephrin Receptor	Cancer
Targefrin is a potent EphA2-targeting agent, acts as an antagonist. Targefrin binds EphA2-LBD with 21 nM dissociation constant and an IC₅₀ value of 10.8 nM. Targefrin induces cellular receptor internalization and degradation in several pancreatic cancer cell lines .

HY-100037

NT157 1 Publications Verification Tyrphostin NT157
NT157 (Tyrphostin NT157) is a selective IRS-1/2 inhibitor that induces Ser-phosphorylation and consequently the degradation of IRS-1/2. NT157 (Tyrphostin NT157) is a first-in-class anti-cancer agent that also targets Stat3 signaling pathway .

HY-119198

NSC745885	Apoptosis Histone Methyltransferase	Cancer
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers .

HY-114312

MD-224 4 Publications Verification	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (MDM2) degrader based on the proteolysistargeting chimera (PROTAC) concept. MD-224 consists of ligands for Cereblon and MDM2. MD-224 induces rapid degradation of MDM2 at concentrations <1 nM in human leukemia cells, and achieves an IC₅₀ value of 1.5 nM in inhibition of growth of RS4;11 cells. MD-224 has the potential to be a new class of anticancer agent . MD-224 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13650

Indisulam 5 Publications Verification E 7070	Molecular Glues Carbonic Anhydrase	Cancer
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15 .

HY-129611

Bromelain	Apoptosis	Inflammation/Immunology Cancer
Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .

HY-132604

Fazirsiran ARO-AAT	Small Interfering RNA (siRNA)	Metabolic Disease
Fazirsiran (ARO-AAT) is a second-generation RNAi agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.

HY-132604A

Fazirsiran sodium ARO-AAT sodium	Small Interfering RNA (siRNA)	Metabolic Disease
Fazirsiran sodium is a second-generation RNAi agent. Fazirsiran sodium consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran sodium can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.

HY-N2214

7-O-Methylaloeresin A
7-O-Methylaloeresin A is 5-methylchromone glycoside isolated from Commiphora socotrana (Burseraceae). 7-O-Methylaloeresin A exhibits good activity against multiple agent resistant Staphylococcus aureus (NCTC 11994) and Salmonella typhimurium (ATCC 1255) with MIC values of 0.72 and 0.18 mM, respectively. 7-O-Methylaloeresin A has antioxidant activities, gives IC50 values of 0.026 mM and 0.021 mM for DPPH and 2-deoxyribose degradation assay, respectively.

HY-19671

Apomine SR-45023A; SR 9223i; SK&F-99085	Apoptosis	Cancer
Apomine (SR-45023A) is an antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. It can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. In addition, Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer .

HY-149539

PLM-101	FLT3 RET	Cancer
PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po) .

HY-W250129

2,3,4,5-Tetrafluorobenzoyl chloride	Biochemical Assay Reagents	Others
2,3,4,5-Tetrafluorobenzoyl chloride is a fluorinated organic compound that belongs to the class of benzoyl chlorides. It is a colorless liquid with a pungent smell and is mainly used as an intermediate in the synthesis of various pharmaceutical and pesticide compounds. 2,3,4,5-Tetrafluorobenzoyl chloride is an acylating agent that can react with a variety of nucleophiles, including amines, alcohols, and thiols, to form amides, esters, or thioesters, respectively. Its unique fluorine-containing structure can impart desired properties to target molecules, such as increased lipophilicity or increased stability against metabolic degradation. However, due to its high reactivity and potential health hazards, proper safety measures and handling procedures must be followed when using this compound.

Cat. No.	Product Name	Category	Target	Chemical Structure